Tivantinib
Tivantinib is an inhibitor of MET and GSK-3α/β that exhibits anticancer chemotherapeutic activity. Tivantinib inhibits proliferation of non-small cell lung cancer (NSCLC) cells and is currently undergoing clinical trials, showing improvements in time to progression and overall survival in the treatment of hepatocellular carcinoma.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18976663
| Cas No. |
1000873-98-2 |
|---|---|
| Purity |
≥98% |
| Formula |
C23H19N3O2 |
| Formula Wt. |
369.42 |
| Synonym |
ARQ-197 |
| Appearance |
Light pink powder |
Remsing Rix LL, Kuenzi BM, Luo Y, et al. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol. 2014 Feb 21;9(2):353-8. PMID: 24215125.
Rimassa L, Personeni N, Simonelli M, et al. Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma. Future Oncol. 2013 Feb;9(2):153-65. PMID: 23414466.
Bagai R, Fan W, Ma PC. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs. 2010 Jun;13(6):404-14. PMID: 20506063.
